MATRIXX Software Achieves 5G Performance Benchmarks with IBM Cloud for Telecommunications
3.5.2021 13:02:00 EEST | Business Wire | Press release
MATRIXX Software, a global leader in cloud native, 5G monetization solutions, today announced performance results from its IBM Cloud for Telecommunications implementation. Anticipating the urgent need of Communications Service Providers (CSPs) to monetize their 5G investments, MATRIXX Software’s 5G CCS established a performance milestone of 200K transactions per second (TPS) across 100M subscribers running on IBM Cloud for Telecommunications.
With average end-to-end latency of 7.4 milliseconds across all operations, including network gateways and routing, this performance benchmark demonstrates that MATRIXX on IBM Cloud can enable CSPs to run critical network workloads in the cloud at the same or better performance levels as on-premise. MATRIXX successfully delivered seamless scalability for an efficient, flexible cloud native charging solution, which opens the door for CSPs to experiment with new ways of monetizing 5G workloads.
This is an important milestone as 5G represents a $667B opportunity by 2026 and impacts every industry. To explore and test new revenue streams, CSPs need to accelerate their network transformation to handle increased traffic from new services and devices. With more than 30 billion IoT devices predicted by 2025, telco networks and IT infrastructure will need proven capability to scale both vertically and horizontally if they are to manage the 10-20x growth in traffic anticipated from 5G.
Using a simulated blend of 4G and 5G traffic, MATRIXX used the IBM Cloud for Telecommunications, built on Red Hat OpenShift, to provide more flexibility in harnessing data across cloud and on-premises environments. The performance benchmark demonstrates how together, MATRIXX and IBM Cloud for Telecommunications can deliver consistent throughput and latency, which helps enable providers to run critical network workloads such as charging in the cloud.
“As telcos deploy 5G network infrastructure, they are looking for validation of new revenue models that 5G enables,” said Marc Price, MATRIXX CTO. “We have collaborated with IBM to achieve industry-leading metrics on its IBM Cloud for Telecommunications, showcasing for CSPs how their 5G monetization strategies will be achievable as the number and diversity of connected devices increases exponentially.”
This is the first lab outcome since MATRIXX joined IBM’s partner ecosystem. These results demonstrate the seamless scalability of MATRIXX’s patented converged charging technology when combined with the IBM Cloud for Telecommunications. Working in close collaboration, IBM’s Hybrid Cloud Build Team and MATRIXX have developed a blueprint for best practices and configuration requirements they can deliver to CSP’s to address their unique performance targets.
“As 5G transforms the telco industry, many operators face the challenge of managing growing volumes of data, voice, and multi-media services from millions of end users. The IBM Cloud for Telecommunications is designed to address these specific challenges and transform their networks into flexible platforms that can efficiently scale,” said Steve Goetz, Vice President & Senior Partner of Global Telecommunications, Media & Entertainment Industry at IBM. “As a leading Network and 5G Transformation partner, IBM Global Business Services is proud to support our ecosystem partner MATRIXX to help them achieve such a notable milestone. These results will accelerate business transformation and agility as customers modernize enterprise applications and infrastructure to unlock the power of 5G and edge.”
With innovations in business rule execution, transaction processing, data management and clustering, the cloud native MATRIXX 5G CCS delivers consistent throughput and latency within heterogenous network environments, managing sophisticated price plans, across hundreds of millions of unique subscribers and devices.
MATRIXX is part of IBM's partner ecosystem collaborating on the IBM Cloud for Telecommunications to help network equipment providers, independent software vendors (ISVs), software-as-a-service providers, and hardware partners accelerate business transformation by unlocking the power of 5G and edge. The IBM Cloud for Telecommunications is an open, hybrid cloud architecture that leverages Red Hat OpenShift and IBM Cloud Satellite to enable clients to deploy IBM Cloud services anywhere: on the cloud, on premises or at the edge, while addressing unique industry regulatory and security requirements. The IBM Hybrid Cloud Build Team is an elite team dedicated to help partners maximize the value of open hybrid cloud environments and unlock the power of AI for their business and customers.
To learn more about the collaboration between MATRIXX and IBM, watch this video interview between Marc Price and Omkar Nimbalkar, VP WW Hybrid Cloud Build Team at IBM Hybrid Cloud Ecosystem Group.
About MATRIXX Software
MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS), enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005238/en/
Contact information
Jennifer Kyriakakis
mediainquiry@matrixx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom